Mobile
Recherche simple
Recherche avancée
Recherche multicritère
Qui sommes-nous ?
Connexion
Inscription
French
English
Kusajili – Centralise les essais cliniques mondiaux
Résultat
de votre recherche par promoteur : Novo Nordisk A/S
Femme et Homme Max 99 ans
Novo Nordisk A/S
MAJ Il y a 5 ans
A randomised, single-dose, double-blind, placebo-controlled, parallel-group trial to assess clinical efficacy of NNC 0142-0000-0002 in subjects with active rheumatoid arthritis
To evaluate the change in disease activity following a single subcutaneous (s.c.) dose of NNC 142-0002 compared to placebo in subjects with active rheumatoid arthritis (RA) on background methotrexate ...
Pays
Aucun
Organes
Aucun
Spécialités
Aucune
Essai clos aux inclusions
Plus d'informations
Femme et Homme Max 99 ans
Novo Nordisk A/S
MAJ Il y a 5 ans
A randomised, controlled, parallel, open-labelled, multinational, trial comparing the efficacy and safety of step-wise addition of insulin aspart according to the largest meals (Basic Basal Plus regimen) or the largest prandial increments (Advanced Basal Plus regimen) in combination with once daily insulin detemir and OAD treatment, in subjects with type 2 diabetes
To investigate if IAsp added step-wise (1-2-3) in a Basic regimen (according to the largest meal, and titrated based mainly on pre-meal SMPG) is equivalent to IAsp added step-wise (1-2-3) in an Advanc...
Pays
Aucun
Organes
Aucun
Spécialités
Aucune
Essai clos aux inclusions
Plus d'informations
Femme et Homme Max 99 ans
Novo Nordisk A/S
MAJ Il y a 5 ans
A clinical trial comparing glycaemic control and safety of insulin degludec/liraglutide (IDegLira) versus insulin glargine (IGlar) as add-on therapy to SGLT2i in subjects with type 2 diabetes mellitus Ensayo clínico para comparar el control glucémico y la seguridad de insulina degludec/liraglutida (IDegLira) frente a insulina glargina (IGlar) como tratamiento complementario a SGLT2i en sujetos con diabetes mellitus tipo 2
To confirm the effect of insulin degludec/liraglutide (IDegLira) in terms of glycaemic control in subjects with type 2 diabetes mellitus (T2DM) on previous treatment with sodium-glucose cotransporter ...
Pays
Aucun
Organes
Aucun
Spécialités
Aucune
unknown
Plus d'informations
Femme et Homme Max 99 ans
Novo Nordisk A/S
MAJ Il y a 5 ans
A 52-week randomised, controlled, open label,multicentre, multinational treat-to target trial comparing efficacy and safety of SIBA and insulin glargine both administered once daily in a basal-bolus regimen with insulin aspart as mealtime insulin ± treatment with metformin, ± pioglitazone in subjects with type 2 diabetes currently treated with insulin qualifying for intensified treatment
To confirm the efficacy of SIBA + insulin aspart ± OAD(s) in controlling glycaemia with respect to change from baseline in HbA1c after 52 weeks of treatment. This is done by comparing the difference i...
Pays
Aucun
Organes
Aucun
Spécialités
Aucune
Essai clos aux inclusions
Plus d'informations
Femme et Homme Max 99 ans
Novo Nordisk A/S
MAJ Il y a 5 ans
Efficacy and safety of oral semaglutide versus placebo in subjects with type 2 diabetes mellitus treated with diet and exercise only
To compare the effects of three dose levels of once-daily oral semaglutide (3, 7 and 14 mg) versus once-daily placebo on glycaemic control in subjects with type 2 diabetes mellitus treated with diet a...
Pays
Aucun
Organes
Aucun
Spécialités
Aucune
unknown
Plus d'informations
Femme et Homme Max 99 ans
Novo Nordisk A/S
MAJ Il y a 5 ans
Treatment intensification with biphasic insulin aspart 30 in subjects with type 2 diabetes inadequately controlled on sitagliptin and metformin
To compare the efficacy in terms of glycaemic control of biphasic insulin aspart 30 (BIAsp 30) twice daily + sitagliptin + metformin, BIAsp 30 twice daily + metformin and BIAsp 30 once daily + sitagli...
Pays
Aucun
Organes
Aucun
Spécialités
Aucune
Essai clos aux inclusions
Plus d'informations
Femme et Homme Max 99 ans
Novo Nordisk A/S
MAJ Il y a 5 ans
Efficacy and Safety of FIAsp Compared to Insulin Aspart in Combination with Insulin Glargine and Metformin in Adults with Type 2 Diabetes
To confirm efficacy of treatment with meal time faster-acting insulin aspart (FIAsp) in terms of glycaemic control measured by glycosylated haemoglobin (HbA1c) after 26 weeks of randomised treatment, ...
Pays
Aucun
Organes
Aucun
Spécialités
Aucune
unknown
Plus d'informations
Femme et Homme Max 99 ans
Novo Nordisk A/S
MAJ Il y a 5 ans
A multi-center, randomized, double-blind, parallel group, placebo controlled trial to evaluate the efficacy and safety of activated recombinant factor VII (rFVIIa/NovoSeven®/NiaStase®) in severely injured trauma patients with bleeding refractory to standard treatment
To evaluate the efficacy and safety of rFVIIa (NovoSeven®/NiaStase®) compared to placebo as an adjunct to standard treatment of trauma patients with active hemorrhage refractory to blood component the...
Pays
Aucun
Organes
Aucun
Spécialités
Aucune
Essai clos aux inclusions
Plus d'informations
Femme et Homme Max 99 ans
Novo Nordisk A/S
MAJ Il y a 5 ans
Efficacy and safety of FIAsp in a basal-bolus regimen versus basal insulin therapy, both in combination with metformin in adult Subjects with type 2 diabetes
To confirm superiority of meal-time Faster-acting insulin aspart (FIAsp) in a full basal-bolus regimen versus basal insulin therapy, both in combination with metformin, in terms of glycaemic control a...
Pays
Aucun
Organes
Aucun
Spécialités
Aucune
Essai clos aux inclusions
Plus d'informations
Précédent
8
9
10
11
12
13
14
15
16
17